Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion  

作　　者：Yuan-Yuan Zhong Chong Tang Lan-Yue Zhang Xue-Dong Zhang Shu-Lin Liu 

机构地区：[1]The First Affiliated Hospital of Chongqing Medical University,Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases,Chongqing 400016,China

出　　处：《International Journal of Ophthalmology(English edition)》2024年第10期1837-1842,共6页国际眼科杂志（英文版）

基　　金：Supported by the National Natural Science Found of China(No.81870673,No.81800814,No.82201168).

摘　　要：AIM:To evaluate the efficacy,timing of retreatment and safety of dexamethasone(DEX)implant on macular edema(ME)secondary to diabetic retinopathy(DME)and retinal vein occlusion(RVO-ME)patients who were refractory to anti-vascular endothelial growth factor(VEGF)treatment.METHODS:This retrospective study included 37 eyes received at least one DEX implant treatment for DME or RVO-ME between January 1,2019,and January 1,2023.These refractory DME and RVO-ME cases received at least 5 anti-VEGF injections and failure to gain more than 5 letters or a significant reduction in central retinal thickness(CRT).The best corrected visual acuity(BCVA)and CRT were measured at baseline,and at 1,3,4 and 6mo post-DEX implant injection.Adverse events such as elevated intraocular pressure(IOP)and cataract were recorded.RESULTS:For RVO cases(n=22),there was a significant increase in BCVA from 0.27±0.19 to 0.35±0.20 at 6mo post-DEX injection(P<0.05)and CRT decreased from 472.1±90.6 to 240.5±39.0μm at 6mo(P<0.0001).DME cases(n=15)experienced an improvement in BCVA from 0.26±0.15 to 0.43±0.20 at 6mo post-DEX implant injection(P=0.0098),with CRT reducing from 445.7±55.7 to 271.7±34.1μm at 6mo(P<0.0001).Elevated IOP occurred in 45.9% of patients but was well-controlled with topical medications.No cases of cataract or other adverse events were reported.CONCLUSION:DEX implants effectively improve BCVA and reduce CRT in refractory DME and RVO-ME.Further research with larger cohorts and longer follow-up periods is needed to confirm these findings and assess long-term outcomes.

关 键 词：macular edema dexamethasone implant anti-vascular endothelial growth factor retinal vein occlusion diabetic retinopathy 

分 类 号：R774.5[医药卫生—眼科]